So here's what's happening with GoodRx Holdings (GDRX) on Thursday: the stock is up in premarket trading, and it's not just random noise. The company made an announcement that actually matters for its business—they're expanding access to Eli Lilly and Company's (LLY) new oral GLP-1 medication, Foundayo.
Think of it this way: GoodRx helps people find cheaper prescriptions, and now they're making it easier for self-pay consumers to get their hands on one of the hottest drug categories out there. Eligible customers can access Foundayo starting at $149 per month through GoodRx. They're also expanding access to Zepbound, another Lilly drug, available at over 70,000 pharmacies nationwide starting at $299 per month for self-pay patients. In a market where weight-loss drugs are all the rage, this is a smart move to tap into that demand.
Earnings & Analyst Outlook
Now, let's talk about the numbers. GoodRx is scheduled to report earnings on May 6, 2026 (estimated). The expectations are a bit mixed: analysts are looking for EPS of 5 cents, down from 9 cents, and revenue of $183.88 million, down from $202.97 million. The valuation sits at a P/E of 23.9x, which suggests it's fairly priced—not cheap, not expensive.
Despite those lower estimates, analysts still have a Buy rating on the stock, with an average price target of $5.76. But it hasn't been all sunshine lately. Recent moves include Wells Fargo lowering its target to $3.50 on March 4, Citigroup doing the same on March 3, and Goldman Sachs cutting to $2.50 on March 2. So, while the overall sentiment is positive, there's some caution in the air as earnings approach.
Price Action
As for how the market is reacting, GoodRx shares were up 4.66% at $2.24 during premarket trading on Thursday. That's a decent pop, and it shows investors are paying attention to this expansion news. In a world where every stock move gets overanalyzed, it's refreshing to see a clear catalyst like this driving action.
